Bretylium kinetics in renal insufficiency

Area of Science:

• Pharmacokinetics
• Nephrology
• Critical Care Medicine

Background:

• Bretylium tosylate is an antiarrhythmic agent.
• Renal impairment can significantly alter drug pharmacokinetics.
• Understanding bretylium tosylate's behavior in renal dysfunction is crucial for patient safety.

Purpose of the Study:

• To investigate the pharmacokinetic profile of bretylium tosylate in patients with varying degrees of renal impairment.
• To determine the relationship between bretylium tosylate kinetics and renal function markers, specifically creatinine clearance.
• To provide guidance for adjusting bretylium tosylate dosage in patients with renal dysfunction.

Main Methods:

• Single intravenous dose administration of bretylium tosylate.
• Plasma concentration monitoring over time.
• Calculation of pharmacokinetic parameters (clearance, half-life, volume of distribution).
• Correlation analysis with creatinine clearance.
• Evaluation in anephric patients undergoing hemodialysis.

Main Results:

• Maximum plasma bretylium concentrations, normalized to dose, strongly correlated with creatinine clearance.
• Drug elimination was reduced in patients with creatinine clearance below 30 ml/min/1.73 m², with prolonged half-life.
• Renal and total body clearance of bretylium tosylate decreased with deteriorating renal function.
• Hemodialysis showed a modest increase in bretylium clearance but did not significantly eliminate the total body load.
• A patient's reduced total clearance over a year correlated with renal function decline and altered volume of distribution.

Conclusions:

• Strong linear relationships exist between renal/total clearance, beta, and creatinine clearance.
• These relationships can inform dosage adjustments for bretylium tosylate in patients with renal impairment.
• Careful consideration of renal function is essential for optimizing bretylium tosylate therapy.